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Tackling issues in the path toward 
clinical translation in brain 
conditioning: Potential offered by 
nutraceuticals
Joseph S Tauskela, Miled Bourourou1, Nicolas Blondeau1
Abstract:
Brief periods of ischemia have been shown in many experimental setups to provide tolerance 
against ischemia in multiple organs including the brain, when administered before (preconditioning) 
or even after (postconditioning) the normally lethal ischemia. In addition to these so‑called ischemic 
conditionings, many pharmacological and natural agents  (e.g.,  chemicals and nutraceuticals) 
can also act as potent pre‑ and post‑conditioners. Deriving from the original concept of ischemic 
preconditioning, these various conditioning paradigms may be promising as clinical‑stage therapies for 
prevention of ischemic‑related injury, especially stroke. As no proven experimentally identified strategy 
has translated into clinical success, the experimental induction of neuroprotection using these various 
conditioning paradigms has raised several questions, even before considering translation to clinical 
studies in humans. The first aim of the review is to consider key questions on preclinical studies of 
pre‑ or post‑conditioning modalities including those induced by chemical or nutraceuticals. Second, 
we make the argument that several key issues can be addressed by a novel concept, nutraceutical 
preconditioning. Specifically, α‑linolenic acid (alpha‑linolenic acid [ALA] an omega‑3 polyunsaturated 
fatty acid), contained in plant‑derived edible products, is essential in the daily diet, and a body of work 
has identified ALA as a pre‑ and post‑conditioner of the brain. Nutritional intervention and functional 
food development are an emerging direction for preventing stroke damage, offering the potential to 
improving clinical outcomes through activation of the endogenous protective mechanisms known 
collectively as conditioning.
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Introduction
Stroke represents a leading cause of death in developed and developing 
countries. Stroke can be considered as a 
“brain attack” because of its rapid onset 
and often devastating consequences. 
The core lesion is irreversible, leading to 
functional impairments, paralysis, speech, 
motor, and cognitive deficits, all of which 
are associated with long-term disability 
and frequent psychiatric complications 
such as dementia, anxiety disorders, and 
poststroke depression.[1] Stroke has an 
incidence of approximately 250–400 in 
100 000 cases and a mortality rate of 
around 30%, so stroke remains as a major 
challenge in modern medicine.[2,3] So far, 
the most accepted treatment in the clinic 
to counteract ischemic stroke is tissue type 
plasminogen activator, but its therapeutic 
window is restricted to 4.5 h after stroke 
onset.[4,5] While achieving recanalization 
using mechanical clot disruption, locally 
injected thrombolytic agents, or both 
intra-arterial thrombolysis and mechanical 
clot removal in cerebral ischemia is also the 
focus of intense investigations,[6] the lack of 
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pharmacological treatment for ischemic stroke resulting 
from the poor translation of neuroprotective approaches 
from experimental models to clinical trials accentuates 
the necessity of considering alternative methods for 
protecting the brain.
Some scientists see great potential in “brain conditioning,” 
a concept that was first associated with the discovery 
of preconditioning. The term preconditioning was 
introduced as early as in the 1960s,[7,8] despite the 
fact that most attribute the origins of this concept 
to Murry et al. in 1986 in the field of myocardial 
infarction.[9] Since the original description of this 
phenomenon, preconditioning has been demonstrated 
in almost all mammals including humans and has been 
established in many other tissues including the brain. 
Preconditioning of the brain by imposing a stressful but 
nondamaging stimulus is an established experimental 
modality that triggers a transient adaptive response able 
to substantially reduce neuronal injury resulting from 
subsequent exposure to an otherwise harmful stimulus 
(for review see[10]). A plethora of preclinical evidence 
has not only established that ischemic “conditioning” 
is neuroprotective but also that brain preconditioning 
may be achieved by drugs, environmental stimuli, and 
natural agents such as nutraceuticals, in numbers that 
approach previously discovered, acute neuroprotectant 
candidates. Indeed, the experimental demonstration that 
certain nutrients can act as “natural preconditioners” 
to increase brain resistance against stroke provides 
a basis for the use of dietary supplementation as a 
natural product “nutraceutical” capable of reducing the 
incidence of stroke and its deleterious consequences (for 
review see[11-13]). Being mindful that diet and physical and 
mental activity may be also viewed as an innate form 
of preconditioning, the “conditioning” phenomenon 
appears to be a promising and potent approach to 
consider translational prospects.
The overarching theme of a wide range of acute 
neuroprotective treatments in clinical translation has been 
one of failure. Lessons–learned from these experiences 
must be utilized in the preclinical evaluation of emergent 
neuroprotective modalities, and this includes brain 
conditioning. It is crucial to evaluate preconditioning as 
any other drug therapy and in particular, to determine its 
strengths but, perhaps more importantly, to determine 
weaknesses. In this regard, it can be quite useful to 
evaluate preconditioning at the level of in vitro models 
of stroke. Such preclinical studies on brain conditioning 
are not typically incorporated into approaches for clinical 
translation, due to their reductionist nature, even though 
proof of concepts, discovery of the pleiotropic nature of 
numerous preconditioning modalities, and weaknesses 
is usually first demonstrated at this level.[14] At the 
in vivo stroke model level, as long ago as 1999, a series 
of criteria from the Stroke Therapy Academic Industry 
Round Table (STAIR) were recommended to identify 
neuroprotective agents with the best chance of success 
in clinical trials. The initial six recommendations were 
outlined in defining the drug dose–response curve and 
its time window of efficiency in well-characterized 
models of both permanent and transient occlusions, 
spanning rodents to gyrencephalic species, based on 
blinded and physiologically controlled reproducible 
studies evaluating histological and functional outcomes 
assessed acutely and long term.[15] Since then, substantial 
advances have occurred, and the STAIR preclinical 
recommendations have been regularly updated.[16] To 
improve the quality of preclinical studies of purported 
conditioning therapies toward clinical application, 
STAIR recommendations should be closely followed 
in studies to identify robust conditioning modalities to 
assist in averting continued failures in neuroprotective 
clinical trials in stroke.
What Exactly is Preconditioning and what 
Discerns Preconditioning from Drug 
Pretreatment?
Cerebral ischemic preconditioning exposes the 
brain to a nonlethal disruptive event, from which 
follows a temporal window of tolerance so that a 
subsequent major ischemic insult does not create as 
much (or no) damage. Transient ischemic attacks are 
thus able to provoke ischemic tolerance in the brain. 
Clinical application of preconditioning has usually 
been viewed as an impracticality since neurons had 
to be stimulated to a point close to death in order 
for ischemic preconditioning to induce this state of 
tolerance; the state of tolerance is limited in duration, 
requiring a more accurate assessment of when an 
ischemic attack will occur, which is a very difficult 
task indeed for the vast majority of strokes. However, 
it has been now shown that mild preconditioning by 
certain drugs (chemical preconditioning as opposed 
to ischemic preconditioning induced by transient 
ischemic attack) and postconditioning exposures can 
yield equivalent neuroprotective effects. The rationale 
is that neurons would not need to be taken to the 
“brink of death” with some drug inducers. As one 
example at the mechanistic level, our investigations into 
preconditioning based on chronic elevations in excitatory 
synaptic neurotransmission to induce downregulated 
synaptic scaling is a modality based closer to normal 
neuronal homeostasis.[14] On a potentially more practical 
level, we introduce nutraceutical preconditioning in 
sections below.
Confusion between terminologies and methods used 
in the conditioning field may also have impeded 
interest and research efforts. While very nice attempts 
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to provide conceptual integration and clear definitions 
of this field were made,[10,17] in view of an increasing 
publication rate of studies of brain ischemic conditioning, 
caution is warranted in retaining clear definitions 
of the several related, but different concepts in the 
conditioning field will certainly prove to be useful. 
Drug-induced preconditioning should not be confused 
with pretreatment. The difference between drug therapy 
and chemical preconditioning is that in chemical 
preconditioning, the drug used as preconditioner 
would reprogram the cell activating broad protective 
responses (genetic and molecular)[18] whereas an acutely 
applied drug acts on specific cellular signaling activated 
by ischemia. In essence, no matter the stimulus, the 
preconditioner does not simply activate competing 
protective mechanisms or inhibit injury pathways to 
counteract the injury cascades triggered by ischemia 
but actually profoundly improves the resistance of the 
cell, its perception, and response to ischemia.[10,17,19] In 
some respects, preconditioning is a sort of “hormesis.” 
This term hormesis is used to describe a dose–response 
relationship phenomenon characterized by low-dose 
stimulation and high-dose inhibition, being independent 
of chemical/physical agents and biological models.[20,21] 
Nevertheless, the “overall” preconditioning phenomenon 
extends beyond hormesis: a low level of stress triggers 
pathways that protect the organs/cells against a 
subsequent higher level of stress. Hence, preconditioning 
is an adaptive response, in which the first stimulus 
influences the effect of a second stressor. Therefore, the 
terminology of preconditioning/preconditioner should 
apply to all stressors, drugs, and natural compounds 
that are able to induce tolerance within a certain time 
frame; the temporal aspect is important as a delay is 
required for the transition to a tolerant state, and in 
fact, the necessity for a delay after preconditioning 
onset is an essential hallmark of the preconditioning 
phenomenon. The duration of the delay required may 
vary depending on the type of preconditioning model 
employed, particularly in the case of the induction of 
preconditioning by a molecule (chemical or nutraceutical 
preconditioning).
The preconditioning effect requires time for genomic 
changes and protein synthesis, in contrast to the vast 
majority of drugs intended to exert an acute effect. 
Thus, chemical preconditioning provokes the creation 
of protective pathways, which a conventional drug 
treatment is not designed for. Moreover, preconditioning 
is pleiotropic by nature, targeting several pathways of 
ischemic injury, and acting at multiple time points, 
whereas drug therapy is not designed for this flexibility 
and must act directly on specific cellular targets to avoid 
side effects.[22] Preconditioning possesses a “built-in 
redundancy” in generating a protective effect, which 
could lead to the identification of a drug therapy able to 
induce preconditioning. Summarizing, preconditioning 
genetically reprograms the response of the brain to 
ischemia and favors cell survival by inducing new 
protective pathways as opposed to drug therapies, 
which suppress deleterious effectors produced by 
ischemia.
In the literature, the terms preconditioning and 
“exposure” have often been confused while they do 
not refer to the same idea: preconditioning is the fact of 
activating the tissue by exposure to a stimulus known 
as a preconditioner, whereas tolerance is the result of 
the preconditioning. Tolerance exists when the tissue is 
protected as if it was “trained” to respond to an otherwise 
disruptive event such as ischemia.
In the field of “cell conditioning,” another experimental 
protective modality targeting ischemia was also 
established first in the myocardium in 2003: 
postexposure to a low intensity ischemic stimulus 
after a massive (normally lethal) exposure to the same 
type of stimulus has been shown to be as effective as 
ischemic preconditioning in reducing infarct size.[23] 
Postconditioning is different from preconditioning in 
the way that the conditioning refers to the action of 
inducing a low degree of stress after exposure to a high 
level of stress of the same sort. In the field of cerebral 
protection, ischemic postconditioning, induced by 
repetitions of transient interruption in blood flow during 
early reperfusion, also reduces ischemic injury to levels 
similar to that achieved with preconditioning.[24-26] In 
addition, both preconditioning and postconditioning 
seem to activate a common subset of cellular signaling, 
consistent with findings that protection is not additive 
when combined, as opposed to being used separately.
The field of brain postconditioning is relatively 
immature, but given an increasing number of 
publications, the term postconditioning risks being 
confused with posttreatment, particularly for 
the evaluation of nonischemic-based chemical or 
nutraceutical postconditioners. As for preconditioning, 
postcondi t ioning di f fers  cons iderably  f rom 
posttreatment. The time frame is an important 
consideration, as “rapid” postconditioning may not 
face the same translational issues associated with 
posttreatment. Indeed postconditioning-induced 
activation of pleiotropic protective pathways could be 
rapid enough to protect the brain from cell death due 
to an ability to potentially target temporal and regional 
complexities of stroke-induced pathologic signaling 
pathways. In contrast, most posttreatment-based 
pharmacology is designed to block one step of the 
neurotoxic ischemic cascade. Moreover, “delayed” 
postconditioning is of high interest as it could be 
efficiently applied several days after the ischemia. 
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Such a treatment can result in blocking not only 
the deleterious pathways driven by glutamate 
excitotoxicity (peri-infarct depolarizations) but also 
more delayed neurotoxicity mechanisms such as 
inflammation and programmed cell death. As well, 
postconditioning can enhance restorative mechanisms 
such as neurotrophic factor production and also 
favors the preservation of the vasculature to improve 
the perfusion of brain regions experiencing low rates 
of perfusion (penumbra), thereby preventing the 
expansion of the damage.[27,28] Consequently, ischemic 
postconditioning and remote postconditioning may 
possess higher translational value than preconditioning 
counterparts[29] and postconditioning agents hold 
significant promise as clinical-stage therapies for 
reducing ischemic damage.
How can Preconditioning Concepts aid in 
Clinical Translation to the Brain?
The issues and frustration of failures of human clinical 
trials in ischemia are a common theme in protection 
of the heart and the brain. Cardioprotection from 
ischemia still needs improvement, and myocardium 
conditioning remains a viable option to continue to 
pursue. Preconditioning and postconditioning applied 
to myocardial infarction predate these concepts 
in the brain. Postconditioning may represent an 
eventual influence for the future management of acute 
myocardial infarction, based on several clinical studies 
showing that postconditioning the human myocardium 
of patients undergoing percutaneous coronary 
intervention by repetitively inflating and deflating an 
angioplasty balloon displayed a reduced infarct size.[30,31] 
Nevertheless, the heterogeneity in procedures in the 
management of acute myocardial infarction makes 
the systematic implementation of postconditioning 
still challenging in real-world scenarios. While such 
studies assist in anticipating issues likely to arise in 
translating ischemic cerebral pre- and post-conditioning 
into therapy, they also strengthen the clinical value of 
understanding the molecular mechanisms associated 
with conditioning that will be crucial in the search of 
agents for pharmacological/chemical/nutraceutical 
pre- and post-conditioning.
While similar issues may arise when considering cardiac 
or cerebral preconditioning (or postconditioning) for 
clinical trials, it is clearly established at the preclinical 
level that preconditioning is not limited to a cell type, 
tissue or organ, or to various ischemic pathologies. 
Epileptic preconditioning offering tolerance to 
epilepsy follows a similar process: a milder seizure 
protects the brain from a subsequent more serious 
seizure.[32,33] Moreover, “cross-tolerance” has also 
been described in numerous findings, in which 
preconditioning can trigger resistance to different 
kinds of subsequent insults.[32] One explanation of this 
“cross-tolerance phenomenon” is that several insults 
have some protein degradation-based commonality 
in the mechanism of neurotoxicity including 
excitotoxicity, oxidative stress, and apoptosis. Hence, 
any preconditioner inducing tolerance to either of 
these components may be broadly effective: various 
sublethal insults such as epilepsy, endotoxins, anoxia, 
hyperthermia, and spreading depression were also 
described to promote tolerance to ischemia and 
reciprocally.[10,22,32] The benefit of this phenomenon 
known as “cross-tolerance” against ischemia, 
epilepsy insults dominated by glutamatergic 
excitotoxicity was also observed in chemical (by 
drugs such as adenosine or KATP channel agonists) and 
nutraceutical (alpha-linolenic acid [ALA] and certain 
lysophospholipids) preconditioning.[34-37]
Cerebral preconditioning may thus protect the brain 
from diverse neurodegenerative challenges. While it 
is still unclear whether all cellular signaling activated 
by preconditioning is required for inducing efficient 
tolerance, any activator of one of the major pathways 
may suffice to trigger preconditioning. This has opened 
up research in chemical preconditioning, seeking 
a molecule that could stimulate the mechanisms of 
preconditioning triggering cerebral tolerance.
How to Identify a Preconditioner 
Maximizing the Therapeutic Index and Still 
Meeting Clinical Trial Requirements?
The identification and development of neuroprotective 
preconditioners may address issues accounting for 
why acute neuroprotectants have been a dismal failure 
in clinical stroke trials. A landmark study concluded 
that translation of the acute neuroprotectants to 
clinical trials may have been largely unjustified since 
drugs given to acute stroke patients performed no 
better than those drugs for which only animal testing 
was done, especially based on the long-term and 
clinically relevant outcomes.[38,39] Thus, historically, 
experimental studies focused on demonstrating 
efficacy, but the decision to proceed to clinical 
trials was not based on demonstrable superiority 
relative to other candidates. While considerable 
uncertainty can exist in defining criteria for comparing 
“best-between-class” neuroprotectants, particularly 
in view of the uncertainty surrounding the relative 
importance of various neurotoxic signaling pathways 
activated by ischemia, it is more difficult to understand 
why pursuing “best-in-class” agents has not been 
more aggressively pursued. Using a “lessons-learned” 
approach and adopting to the field of conditioning, 
a conceptual consensus and improved experimental 
[Downloaded free from http://www.braincirculation.org on Tuesday, July 18, 2017, IP: 134.59.171.89]
Tauskela, et al.: Adjusting nutraceutical brain conditioning for translation
82 Brain Circulation ‑ Volume 3, Issue 2, April‑June 2017
methodologies are required to narrow down the choice 
of preconditioning agents to be pursued. Indeed, 
different types of preconditioners, while sometimes 
producing somewhat dissimilar protection, all prove 
somewhat efficient, as the neuronal death is lower with 
any preconditioner used against moderately lethal 
transient ischemia. This is a consistent finding both 
in vivo and in vitro.
We have performed a large body of in vivo testing of 
different forms of preconditioning – ischemic, epileptic, 
chemical, and nutraceutical – against the ischemic 
insult (in vivo model of 6 min of global ischemia) and 
concluded that the best‑in‑class may not be identified 
in such a model, at least as far as determining which 
one offers the greatest degree of neuroprotection. 
Indeed, 6 min global ischemia – considered a lethal 
but not harsh ischemia - conducted on rats kills ~75% 
of hippocampal neurons, while preconditioning by 
sublethal 3 min ischemia preserved almost the entire 
hippocampus. Similarly, cross-tolerance obtained by 
epileptic preconditioning also conferred more than 
90% of cell survival.[32] Chemical preconditioning 
by cromakal im induced approximately  70% 
of protection and by phenylisopropyladenosine 
resulted in 85% of neuronal survival.[34] Nutraceutical 
preconditioning with intravenous injection of particular 
lysophospholipids (lysophosphatidylcholine or 
lysophosphatidylinositol[37]) or by ALA (the long chain 
omega-3 fatty acids precursor contained in plant-derived 
edible products[35,36]) 3 days before the 6 min ischemia 
offered better protection than chemical preconditioning, 
similar to the levels observed with ischemic and epileptic 
preconditioning. Thus, the “brink-of-death” requirement 
for preconditioners appears to have been circumvented 
with nutraceuticals, while not causing any loss in 
tolerance. It will be important to pursue these promising 
results by further head-to-head comparisons against 
harsher ischemia.
The necessity of raising awareness of the importance 
evaluating efficiency of preconditioners is even more 
striking in vitro. Indeed, in rat neuronal cultures 
subjected to oxygen and glucose deprivation (OGD) 
capable of killing 50%–75% of neurons, this neurotoxicity 
was completely ablated by preconditioning by the 
putative mitochondrial KATP opener, diazoxide or 
the antianginal drug, bepridil, but only partially 
prevented by 3-NPA preconditioning but not by other 
nonselective KATP openers, nicorandil or cromakalim, 
while preconditioning by transient glucose and amino 
acid deprivation reduced OGD-induced death from 
about 65% to about 20%.[40-42] In other studies, OGD 
induced more than 50% death of cultured cortical 
neurons, with preconditioning by cycloheximide, 
erythropoietin or hypoxia providing near-complete 
protection; preconditioning by OGD and heat stress 
provided intermediate protection.[43-46]
While there is a clear value in comparing preconditioners 
against the same test insult, to isolate the “best-in-class” 
preconditioners, it is crucial to test these preconditioners 
against more realistic lethal OGD insult capable 
of killing most of the neurons and even harsher 
conditions.[22] As far as we are aware, no studies had 
considered this approach, so we devoted considerable 
attention to comparing preconditioners selected from 
the literature reported to provide protection against 
a test OGD insult capable of causing less than total 
neuronal death (i.e., lethal), except we increased 
the harshness of this insult in our study [Figure 1]. 
Among the 43 putative preconditioners we screened, 
neuroprotection against an OGD insult sufficiently long 
to kill neurons many times over, achieved by extending 
the insult duration well past the threshold required to kill 
all neurons, was observed in 12 cases.[14] This establishes 
that a “ceiling” of neuroprotection is encountered in 
many preconditioners facing an extending exposure to 
OGD (increasing duration from 60 min to 90 min OGD) 
and confirms the value of comparing preconditioners 
against the “harsher” test to resolve the most potent 
preconditioner.
Figure 1: Preconditioning (PC, ischemic, chemical, and nutraceutical) as well as 
the NMDA receptor antagonist, MK‑801, used as an experimental gold‑standard 
neuroprotectant, abolish neurotoxicity usually induced by “normally” lethal 
conditions (sufficient to kill neurons in most of the experimental paradigms). 
Preconditioning failed under harsher supralethal ischemic conditions (sufficient to 
kill neurons many times over), thereby identifying a “ceiling” to such neuroprotective 
approaches. To circumvent this ceiling, the combination of MK‑801 with 
preconditioning extends the potency of neuroprotection – to various degrees 
depending on the nature of preconditioning – against supralethal ischemic 
conditions.[14] This indicates the existence of a neuroprotective “reserve” that should 
be the focus of our attention and the necessity to explore the future therapy in 
harsher model of ischemia to identify the best‑in‑class opportunity
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Does Conditioning Adequately Overcome 
Major Problems Identified in Clinical 
Stroke Trials, which are Primarily Issues 
of Efficacy, Side Effects, and Timing 
of Administration? Are Chemical or 
Nutraceutical Preconditioning Appropriate 
to be Used as a Preemptive Protective 
Approach in Patients at High Risk of Stroke 
or as Postconditioning Therapy?
In the traditional view of preconditioning, such 
as by ischemia, cells have to be stressed and taken 
to the brink of death, so the implementation of 
preconditioning stimuli is risky. Conceptually, this 
risk may also exist with chemical preconditioners 
since many of the compounds used have the capability 
to be neurotoxic. This is not to mitigate the inherent 
value of conditioning but to caution that the dose 
and toxicity of the chemical - and even nutraceutical 
preconditioners - may be one of the major limitations of 
the systematic application in human. In the traditional 
view of preconditioning, another issue of importance 
is the timing of administration. Medication-induced 
preconditioning was viewed as limited to patients who 
already suffered or at elevated risk of ischemic brain 
injury because of the significant risk of undergoing a 
more serious stroke. The tolerant state is not permanent, 
but recent studies are encouraging, showing that 
preconditioning can be continually performed within 
a regular time frame to ensure a constant state of 
tolerance to an impending stroke.[47,48] Therefore, 
the significance and applicability will be better for 
a preconditioner which is easy to administer, well 
tolerated, accessible, inexpensive, and able to induce 
a prolonged state of tolerance to ischemia. The same 
criteria apply for postconditioning procedures or 
postconditioners. Based on these criteria, it is tempting 
to believe that a new future in brain conditioning may 
be based on nutraceutical preconditioning.[11]
Nutraceutical is a term coined from nutrition and 
pharmaceutical fields without any regulatory definition 
and is commonly used in marketing. It refers to foods 
or one of its constituents that provides medical or health 
benefits including the prevention and/or treatment of a 
disease. We and others have made an attempt to redefine 
and limit its definition to agents isolated from foods, 
with efficacy evaluated as medicinal forms, at least at the 
preclinical level.[11,13,49,50] Such a definition should allow 
nutraceutical research to being pursued according to 
(for instance) the STAIR guidelines for stroke investigation.
The concept of nutraceutical preconditioning is supported 
by our recent discovery that an essential nutrient, ALA 
which is an essential omega-3 polyunsaturated fatty 
acid required as part of our daily diet, is an efficient 
brain pre- and post-conditioner against stroke.[12,13,51] 
ALA-induced preconditioning is pleiotropic in nature 
through the activation of multiple endogenous protective 
transduction pathways, in a similar broad fashion as with 
ischemic, epileptic, and other well-established chemical 
preconditioners. As an example, ALA preconditioning 
induced the expression of the neuroprotective HSP70 
heat shock protein, and the expression and activation 
of the transcription factor nuclear factor-kB, within a 
similar time frame and neuronal localization shared by 
ischemic, epileptic, and adenosine and KATP channel opener 
preconditioning.[35,36] ALA preconditioning also reprograms 
the brain, improving its capacity of neuronal plasticity by 
the induction of transcription and transduction of several 
genes involved in neurogenesis and synaptogenesis.[52] 
ALA preconditioning is also multicellular in nature with 
a capability of targeting not only neurons but also the 
entire neurovascular unit, by also triggering brain artery 
vasodilatation.[53] Moreover, the value of nutraceutical 
preconditioning is increased in considering the timing 
and administration routes. Taken prophylactically in the 
diet as is being increasingly recommended to reduce the 
risk of having a stroke,[54,55] ALA preconditioning reduces 
stroke-induced brain damage in an experimental murine 
model of ischemia induced by 60 min of middle carotid 
artery occlusion (MCAo).[56] Since successful translation 
of conditioning modalities, as with any other therapeutic 
opportunities, will depend on the demonstration of 
efficacy provided at the time of reperfusion and on 
functional deficits resulting from stroke, we evaluated 
the effect of ALA postconditioning in the 30 min MCAo 
model, which is recommended for studying long-term 
functional outcomes.[57] ALA postconditioning given 
intravenously during the reperfusion period, as for any 
given drug that may mimic ischemic postconditioning, 
minimizes long-term impairment of the spatial learning 
and memory, evaluated using the Morris water maze test 
at 2 weeks after surgery, and long-term neuronal damage 
in the hippocampus, a brain region supporting memory 
function.[58] Therefore, compared to ischemic or chemical 
postconditioning approaches, ALA postconditioning 
appears promising in circumventing apparent major issues 
in the field ‑ safety, timing, and administration routes.
This novel concept of nutraceutical preconditioning 
is not restricted to ALA but may, in fact, be extend 
to other existing or nutraceuticals to be identified. 
Other compounds extracted from food or plants 
conforming to the definition of nutraceuticals contain 
molecules that have already been demonstrated 
to act as pre- or post-conditioners in in vivo or 
in vitro models of ischemic stroke: these include 
epigallocatechin 3-gallate (green tea), resveratrol (red 
grapes), quercetin (apples), the organosulfur compounds 
allicin (garlic), L-sulforaphane (broccoli), phenolic acids 
such as rosmarinic and carnosic acid (rosemary), and 
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ginseng.[59,60] While the list is not exhaustive, a clear 
proof of the capacity of such compounds – whether 
in functioning as pre- or post-conditioners – may 
support the concept for nutraceuticals being considered 
as conditioners of the brain against ischemia. In 
addition, based on the demonstration that pre- and 
post-conditionings induce cross-tolerance to trauma, 
epilepsy, SCI, and neurodegenerative insults, the 
underlying pleiotropic benefits of nutraceutical 
preconditioning may also prove beneficial in other 
neurologic pathologies.
Conclusion
Despite uncertainties in the field of brain preconditioning 
against cerebral ischemia, nutraceutical pre- and 
post-conditioning holds significant promise and 
represents promising fields of investigation. Both 
pre- and post-conditioning will afford early or delayed 
protection of individuals against strokes, which 
would be a major achievement given the severity of 
brain damage and numerous deaths. Moreover, the 
concept of nutraceutical preconditioning appears 
more “natural” than other drug therapies, by creating 
an overall protective effect with minimization of side 
effects associated with drug therapies. Furthermore, 
the concept of using a natural compound to produce a 
sort of “natural” protection by activating prosurvival 
signaling is appealing (e.g., stimulating endogenous 
mechanisms in a way that reprograms the brain to 
cause protection against ischemia). Nutraceutical 
preconditioning also acts on several levels as it has 
multiple targets, contrary to therapeutic drugs, 
which have a single specific target. This is positive 
in itself as ischemia induces a complex process 
of cellular destruction and needs to be addressed 
on multiple levels. Altogether, such studies foster 
the interest of this novel concept of brain pre- and 
post-conditioning by nutraceuticals because such 
an approach would circumvent most of the issues 
such as the administration routes and timing issues, 
which thus far have plagued the preconditioning 
and neuroprotectant translation to a stroke patient. 
Overall, the field of nutraceutical conditioning against 
cerebral ischemia appears promising, justifying more 
research to be able to fully grasp all its implications, 
and to potentially lead to human clinical trials if 
deemed safe and efficient.
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